Background. The CDC has reported that seasonal influenza in 2017-2018 has been one of the worst on record, with hospitalization rates among the highest recorded, especially among younger age groups (age 50-65, hospitalization rate of 63.1 per 100,000 people compared with 35.1 in last severe season, 2015-2016) . Understanding how antiviral use affects rates and severity of complications is important to inform treatment decisions. This study used real-world US claims data for 3 flu seasons (2014) (2015) (2016) to understand the frequency of flu complications and how intervention with antivirals may affect their occurrence.
Methods. This was a retrospective cohort study using US commercial claims data from the 2014-2016 flu seasons. Patients with a diagnosis code for flu were identified and required to have continuous coverage for at least 365 days before and 91 days after diagnosis. Patients who were prescribed antivirals within 48 hours of the first flu-related encounter during the flu season were identified and propensity score matched to a comparative cohort without antiviral use within 48 hours but comparable baseline health resource utilization (HRU) and comorbidities. All-cause and respiratory-related HRU and costs in the 30 and 91 days after flu diagnosis were analyzed and compared.
Results. A total of 989,530 cases of influenza were identified over 3 flu seasons, with 60.2 percent receiving antiviral therapy (Table 1 ). In the matched sample, greater HRU and costs was identified in the cohort that did not receive antiviral therapy, with 15% vs. 10.4% (P < 0.001) visiting the ER, and 2.8% vs. 0.9% (P < 0.001) being admitted for inpatient care within the first month (Table 2) . Similarly, greater HRU was also seen in respiratory-related HRU and costs in the cohorts that did not receive antiviral therapy. Findings were similar in unmatched cohorts.
Conclusion. In data for the last 3 available flu seasons, flu patients treated with antivirals had less complications, healthcare resource utilization and overall costs than those who did not receive antiviral treatment. Limitations with this kind of study restrict the conclusions that can be made from this analysis, however suggest that treating flu can improve outcomes and resource utilization beyond symptom resolution. Background. Influenza is a common cause of morbidity and mortality in children. This was a retrospective study of hospitalized children with influenza at KKH admitted from January 2013 to December 2014 to compare the type of complications by age and underlying medical conditions.
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Methods. Influenza patients were identified by a positive polymerase chain reaction (PCR) or immunoflourescence antigen from nasopharyngeal swabs. Patients were grouped into neurologic, respiratory, other and no complication. Multinomial regression was used to compare age and complications with underlying disease.
Results. There were a total of 1,272 patients with a median age of 37 months (IQR 13-76 months). Influenza A constituted 76.3% with serotype H3N2 (54.5%), H1N1 (18.2%), unknown (5.4%). Influenza B constituted 22.9% with serotypes: Yamagata (16.3%), Victoria (5.7%). Only 4 patients (0.3%) had sequelae or death. 28% of influenza admissions had complications. The most common being neurologic 44% (n = 156) followed by respiratory 31% (n = 110). The most common clinical complications were: febrile seizure 34.1%, bronchitis/bronchiolitis 9.9%, pneumonia 7.3%. There was a significant difference between complications by male gender (P = 0.001), community acquisition (P = 0.007), influenza type, other positive viruses, comorbidity, asthma/ lung disease, neurologic disease, history of seizures, ICU/High Dependency admissions (all P ≤ 0.001), developmental delay (P = 0.002), Kawasaki disease on aspirin (P = 0.026), gastro-esophageal reflux (P = 0.034) and prescription of oseltamivir (P = 0.003). Neurologic complications occurred especially in the 2-< 5 year age group (37.2%), respiratory complications in the 6-23 month age group (39.1%). Age ≥5 year was more likely to have neurologic complication if they had a history of seizures (OR 14.2, P < 0.001). Age ≥2 years was more likely to have respiratory complications if they had asthma/ lung disease (OR 3.5, P < 0.001).
Conclusion. Although influenza mortality was low, 28% of influenza admissions in children had significant complications. Children with underlying medical problems should routinely receive influenza vaccinations to avoid complicated influenza illness.
Disclosures. Background. Parechovirus-A3 (PeV-A3) is an emerging pathogen causing sepsis and meningoencephalitis in neonates and young infants. We previously reported that maternal antibodies against PeV-A3 are important to protect neonates and young infants from the infection. We showed that all neonates and infants who developed PeV-A3-related diseases had low neutralizing antibody titers (NATs) against PeV-A3 at the onset of disease, subsequently developed high NATs at 3 and 6 months of age. Subsequent changes in NATs against PeV-A3 in children who suffered from PeV-A3-related diseases are currently unknown. Additionally, their long-term neurological outcome is not well described in such population.
Methods. Subjects were PeV-A3-infected infants less than 4 months in Niigata, Japan during 2013-2014, and follow-up serum samples were obtained longitudinally from the patients at 3, 6 months, 1 and 3 years after the infection. NATs against PeV-A3 were measured using LLC-MK2 cells. Neurological outcomes of the patients were evaluated by their pediatricians at their study visits.
Results. We evaluated 45, 34, 33, 26, and 16 serum samples at onset, 3, 6 months, 1 and, 3 years after the infection, respectively. All 45 serum samples at onset had low NATs against PeV-A3 less than 1:32 which was regarded as a cutoff to prevent PeV-A3 infection. Subsequently, the NATs had elevated to the high level (≥1:512) after the infection in all patients. Three years after the infection, all patients except one achieved normal neurodevelopmental milestones. Only one patient who was diagnosed as severe status epileptics due to meningoencephalitis had developmental delay with difficulties in sitting and walking with support.
Conclusion. This study showed that NATs against PeV-A3 sustained high levels in patients who had severe PeV-A3-related diseases in their neonatal or young infantile periods. Neurological outcomes of the patients who suffered from PeV-A3-related diseases seem to be excellent, except for the case with complicated clinical course. Results. From a total of 15,451 patients included, 13,033 were tested and 45%(5831) had positive samples; RSV was predominant (81.3%,4738) all through the study period, followed by IF: 7.6% (440), PIF 6.9% (402) and AV: 4.3%(251). PIV followed a seasonal epidemic pattern predominantly during spring months (September-October). The median age of cases was 8 months (IQR: 4-13 months); 54% of cases were males. The most frequent clinical presentation was bronchiolitis (61%); 53% had previous admissions for respiratory causes, 9% were readmissions. Comorbidity was found in 59.4%: recurrent respiratory disease (47.8%), congenital heart disease (5.7%), chronic neurological disease (6.5%); 8.5% were malnourished, 23% born preterm and 3.3% immunosuppressed; 23.5% had complications, 10.6% hospital-acquired infections. Lethality was 3.5% (14/396).
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Parainfluenza Virus Infection
The following were independent predictors for PIF infection: recurrent respiratory disease odds ratio (OR): 1.65 (95% CI: 1.32-2.08); P < 0.001; readmissions, OR 1.95 (95% CI: 1.34-2.83); P < 0.001; born preterm, OR: 1.58 (95% CI: 1.19-2.10); P = 0.001.
Conclusion. Parainfluenza infection showed an epidemic seasonal pattern (September-October), with higher risk in children with recurrent respiratory disease, prematurity and previous admissions for respiratory causes.
Disclosures. A. Gentile, Sanofi Pasteur: Consultant, Speaker honorarium. Saturday, October 6, 2018: 12:30 PM Background. Human parainfluenza viruses (HPIVs) are one of common causes of respiratory tract infections in children. Among the four serotypes (HPIVs 1-4), little is known about the epidemiology and clinical characteristics of HPIV-4. The aim of this study was to identify the epidemiology and the characteristics of HPIV-4 compared with HPIVs 1-3 in Korean children.
Epidemiology and Clinical Characteristics of Parainfluenza Virus
Methods. We reviewed medical records of children with HPIV who had been admitted at Seoul National University Children's Hospital during 2015-2017. Detection of respiratory viruses in nasopharyngeal aspirates was performed using multiplex reverse transcription polymerase chain reaction. Patients who had underlying medical conditions such as chronic respiratory disease, immunodeficiency, congenital heart disease, or concurrent viral infections were excluded.
Results. Of 12,539 samples, 586 (8.1%) were positive for HPIV. By the exclusion criteria, 137 (23.4%) were finally included: 46 (33.6%) for HPIV-3, 34 (24.8%) for HPIV-1 and -4 respectively, 23 (16.8%) for HPIV-2. During the study period, two seasonal outbreaks were observed in each serotype. HPIV-1 was prevalent in September 2015 and August 2016, while HPIV-2 in August 2015 and July 2017. The peak of HPIV-3 infection occurred in July 2016 and May 2017. HPIV-4 was mostly infected from August to September in 2015 and in June 2017. Regardless of serotypes, HPIV was predominantly observed in boys and among children less than 5 years of age (70%); the median age in HPIV-4 was 3.1 (0-18) years. The most common clinical presentation was cough in all serotypes (78.7-88.2%). Sore throat was mainly presented in HPIV-4 infected patients compared with other serotypes (11.8%; P = 0.029). HPIV-4 infection was more often diagnosed as bronchiolitis (32.4%) compared with HPIV-1 (8.8%; P = 0.016) and -2 (8.7%; P = 0.037). Croup was most frequently diagnosed in children with HPIV-2 (21.7%), but no patients with HPIV-4 had croup (P = 0.008).
Conclusion. We observed seasonal peak in HPIV-4 from late spring to autumn. Lower respiratory tract infection was main clinical manifestation in HPIV-4 among hospitalized patients and HPIV-4 is a common respiratory pathogen causing significant morbidity in Korean children during 2015-2017.
Disclosures. Saturday, October 6, 2018: 12:30 PM Background. Studies suggest that RSV infection early in life is associated with the development of recurrent wheezing, yet, information on large population-based studies among US full-term healthy infants is incomplete. The objective of this study was to evaluate the risk of developing post-RSV recurrent wheezing/ asthma during childhood among full-term infants in a US commercially insured population.
Methods. Retrospective, observational study used data from Truven MarketScan Commercial Claims and Encounters Database (January 1,
